Inspectors could reduce medical device recall rates by 20%

The Food and Drug Administration (FDA) could reduce the amount of recalled medical devices by 20 percent by placing product inspectors on a rotating schedule, according to a study published in Manufacturing & Service Operations Management.

The recall of medical devices strains both manufacturers and consumers, so researchers from Indiana University, University of Wisconsin-Madison and University of Minnesota developed a set of recommendations to decrease medical device recalls.

Over the course of seven years, researchers evaluated 4,767 FDA plant inspections and 2,863 medical device recalls originating from 2,244 different manufacturing plants.

"We found that FDA medical device plant inspection outcomes are highly predictive of future medical device recalls originating from that plant, but only when it is the first time the FDA investigator has inspected that plant," said author George Ball of Indiana University.

Results showed a 21 percent increase in future recall risk following the second time a single investigator inspects the plant; this risk increases to 57 percent the third time the plant is inspected. In response, researchers developed two solutions that could reduce medical device recalls by 20 percent.

Recommendations included having rotating investigators so the same plant is never inspected twice by the same inspector and sequencing investigators so they do not visit the same plant twice in a row. These two steps, while costing an additional $800,00 in travel expenses, results in an average of 100 less medical device recalls.

"Our findings demonstrate that the FDA, and likely other federal regulators must navigate a fine line in their relationships with industry managers," wrote lead author Rachna Shah of the University of Minnesota. "If overly familiar relationships allow complacency to creep in, it comes at a high cost for medical device consumers who are at risk of a significant increase in medical devices failures leading to recalls."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup